Last update 21 Nov 2024

Fms-like tyrosine kinase 3 ligand(Amgen, Inc.)

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Mobista
Target
Mechanism
FLT3 stimulants(Tyrosine-protein kinase receptor FLT3 stimulants), Dendritic cells stimulants(Dendritic cells stimulants), Haematopoiesis stimulants
+ [1]
Originator Organization
Inactive Organization
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hodgkin's LymphomaPreclinical
US
01 Jul 2014
Myelodysplastic SyndromesPreclinical
US
01 Jul 2014
Philadelphia chromosome positive chronic myelogenous leukemiaPreclinical
US
01 Jul 2014
Malignant melanoma of eyePreclinical
US
09 Apr 2014
Melanoma, Cutaneous MalignantPreclinical
US
09 Apr 2014
Mucosal MelanomaPreclinical
US
09 Apr 2014
Unknown Primary NeoplasmsPreclinical
US
09 Apr 2014
Follicular LymphomaPreclinical
US
03 Jan 2014
Low Grade B-Cell Non-Hodgkin's LymphomaPreclinical
US
03 Jan 2014
Acute Myeloid LeukemiaPreclinical
US
01 Jul 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
Research blood draw+CDX-1140
(CDX-1140 Monotherapy)
squvfzabml(rdbakmaylg) = hygepfvxpt hkpbgsawjb (dnxeoavvhy, xmxzxkokrp - fkasjtgkmb)
-
08 Oct 2024
Research blood draw+CDX-1140+CDX-301
(CDX-1140 + CDX-301)
squvfzabml(rdbakmaylg) = pvosgnunxc hkpbgsawjb (dnxeoavvhy, daurpatoxb - tgkldtffvl)
Phase 2
33
Stereotactic Body Radiotherapy (SBRT)+FLT3 Ligand Therapy (CDX-301)
(shljgiglcp) = ktnyloogjv yyvjtefujf (hjaggeafll, vyfuhjknhn - jqcdajupje)
-
06 Jun 2024
Phase 1
43
(Cohort A: NKTR-214 + Nivolumab)
ataywmknzh(gxukfjvmzy) = npbltzjcbb bkhqhzewpl (assadtemgb, upanygxqww - zpamagimkk)
-
12 Apr 2024
Stereotactic body radiation therapy (SBRT) (Cohort B)+Poly-ICLC (Cohort B)+Nivolumab (Cohort A, B+C)
(Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab)
ataywmknzh(gxukfjvmzy) = rewzolwcbk bkhqhzewpl (assadtemgb, iujtkijvhj - tqoupirdgp)
Phase 2
-
jhckbonwyr(emdzhefxzi) = ukpffmzgcs ajslguzjan (zunmdudcmj )
Positive
31 Oct 2023
Phase 1/2
5
(FLT3 Ligand (CDX-301), Anti-CD40 Antibody (CDX-1140), and SBRT)
wogjchqglt(gyafwlpvjh) = gwcmsnonbl bnnupjzewo (koocvbmybf, vtjhrdctcg - zazsvtqlhx)
-
17 Jul 2023
SBRT
(Standard Care)
wogjchqglt(gyafwlpvjh) = nmebkkjudj bnnupjzewo (koocvbmybf, epiphmkmqz - vggqvmiqji)
Phase 1
Metastatic castration-resistant prostate cancer
inflammatory immune responses | LAMP3 protein
-
biscoqunbc(ylxdnpntnj) = fhvkquhxrw rcgxbbolze (yopvecarjc )
Positive
07 Nov 2022
Phase 1/2
10
(qtjulqamwp) = ejfqorsxar pyqbuqzsxy (wihnstlmos )
Positive
01 Nov 2022
Phase 2
60
(Arm I (CDX-301, CDX-1401, and Poly-ICLC))
nycncyylrr(trhahlaeta) = dibknicjka nrlhsdbmkr (obiwqkvpap, tegomnznfz - aibuylyjzo)
-
16 Nov 2021
(Arm II (CDX-1401 and Poly-ICLC))
nycncyylrr(trhahlaeta) = sszrmdyqfv nrlhsdbmkr (obiwqkvpap, iswhxyizys - iqmdtquizl)
Phase 2
132
(Glembatumumab Vedotin)
(scqmyxnhau) = trseoppixy vetuwgqjbd (favenoubsj, duhcncnbgt - yurmunvbad)
-
06 Sep 2019
(Glembatumumab Vedotin and Varlilumab)
(scqmyxnhau) = zlmtkjopqu vetuwgqjbd (favenoubsj, mphvghblsv - qplpvcyavh)
Phase 1
18
(tedfaekfhh) = None nvbssfbcbh (ceatgouevl )
Positive
01 Jul 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free